An example of the improvement with pharmacological therapies is that everolimus (an mTOR pathway inhibitor) in combination with trastuzumab (a HER2 receptor inhibitor) significantly improved survival in patients with trastuzumab-resistant HER2-positive breast cancer [46,47,48,49]. Here, ERBB2 is linked to breast carcinoma.